| Literature DB >> 35441124 |
Kuan Un Wong1, Jingxuan Shi2,3,4, Peng Li2,3,5, Haitao Wang1, Yanwei Jia1,6,7, Chuxia Deng1, Lianmei Jiang8, Ada Hang-Heng Wong1.
Abstract
Chimeric antigen receptor T (CAR-T) cells are cytotoxic T cells engineered to specifically kill cancer cells expressing specific target receptor(s). Prior CAR-T efficacy tests include CAR expression analysis by qPCR or ELISA, in vitro measurement of interferon-γ (IFNγ) or interleukin-2 (IL-2), and xenograft models. However, the in vitro measurements did not reflect CAR-T cytotoxicity, whereas xenograft models are low throughput and costly. Here, we presented a robust in vitro droplet microfluidic assay for CAR-T cytotoxicity assessment. This method not only enabled assessment of CAR-T cytotoxic activity under different fluid viscosity conditions, but also facilitated measurement of CAR-T expansion and dissection of mechanism of action via phenotype analysis in vitro. Furthermore, our data suggested that label-free cytotoxicity analysis is feasible by acquiring data before and after treatment. Hence, this study presented a novel in vitro method for assessment of cellular cytotoxicity that could potentially be applied to any cytotoxicity experiment with varying solvent composition.Entities:
Keywords: chimeric antigen receptor T cell therapy; cytotoxicity assessment; droplet microfluidics; immunotherapy; precision cancer therapy
Year: 2022 PMID: 35441124 PMCID: PMC9014740 DOI: 10.1093/abt/tbac008
Source DB: PubMed Journal: Antib Ther ISSN: 2516-4236